Charles River Laboratories

Current directors and officers who also hold a role at another S&P 500 company.

• Craig B. ThompsonREGN · Director
• Virginia M. WilsonCARR · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. May 11, 2026

   On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). As further discussed below, at the Annual Meeting, the shareholders of the Company approved the Company’s 2026 Long-Term Incentive Plan (the “2026 Incentive Plan”). The Board of Directors of the Company had previously approved and adopted the 2026 Incentive Plan on March 11, 2026, subject to the approval of the shareholders of the Company. The material features of the 2026 Incentive Plan are described in detail under “Proposal 3 - Approval of the 2026 Long-Term Incentive Plan” of the Company’s Definitive Proxy Statement on Schedule 14A for the Annual Meeting filed by the Company with the Securities and Exchange Commission on March 31, 2026 (the “Proxy Statement”).

   Read the 8-K filing
2. Feb 18, 2026

   On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Mr. Coleman will join the company with a tentative start date of April 6, 2026. Mr. Coleman, 58, will join Charles River with over 30 years of strong financial and operational management experience, including more than a decade of senior leadership roles in the healthcare sector. Most recently since 2024, Mr. Coleman has been serving as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., a $1-billion healthcare services business. Prior to this role, he was the CFO of two public companies, DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation. Mr. Coleman served as Executive Vice President and CFO at DENSTPLY from 2022 to 2024.

   Read the 8-K filing
3. Jan 9, 2026

   Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the “Board”) of Charles River Laboratories International, Inc. (the “Company”) announced a leadership transition plan. Mr. James C. Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairman of the Board, and Ms. Birgit Girshick, our Chief Operating Officer, will be appointed as our Chief Executive Officer, each effective as of May 5, 2026 (the “Transition Date”). Following the Transition Date, it is expected that Mr. Foster will remain a non-executive director of the Board. Dr. Martin Mackay, current Lead Independent Director, is expected to become Chair of the Board, effective as of the Transition Date. In addition, Ms.

   Read the 8-K filing
4. Sep 19, 2025

   (c) On September 16, 2025, Charles River Laboratories International, Inc. (the “Company”) filed a current report on Form 8-K under

   Read the 8-K filing
5. Sep 16, 2025

   (b) On September 12, 2025, Flavia H. Pease informed Charles River Laboratories International, Inc. (the “Company”) of her intention to resign from her position as the Company’s Corporate Executive Vice President, Chief Financial Officer effective on September 29, 2025. Ms. Pease’s decision to resign her position is not the result of any disagreements with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices. (c) In connection with Ms. Pease’s departure from the position of Chief Financial Officer, Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, has been appointed by the Company’s Board of Directors to act as the Company’s interim Chief Financial Officer, effective upon the departure of Ms. Pease, until a permanent successor is named. In this role, Mr.

   Read the 8-K filing
6. May 23, 2025

   On May 20, 2025, Charles River Laboratories International, Inc. (the “Company”) and Mr. James C. Foster, Chair, President and Chief Executive Officer of the Company, entered into, and the Board approved, Amendment No. 1 (the “Foster Amendment”) to Mr. Foster’s Amended and Restated Employment Agreement with the Company, dated as of May 18, 2021 (the “Foster Employment Agreement”), which was filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on May 18, 2021. The Foster Amendment extends the term of Mr. Foster’s employment by an additional year (i.e., until February 12, 2027). Except for the extension of the employment term, all other terms and conditions of the Foster Employment Agreement remain unchanged.

   Read the 8-K filing
7. May 7, 2025

   Item 5.02(b) On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board). None of the departures from the Board described herein are due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

   Read the 8-K filing
8. Jan 24, 2024

   Effective January 22, 2024, the Board of Directors (the "Board") of Charles River Laboratories International, Inc., (the "Company") increased the size of the Board from eleven to twelve. Following the size increase of the Board, the Board filled the vacancy and appointed Ms. Reshema Kemps-Polanco to the Board. Ms. Kemps-Polanco has been appointed to the Company's existing Compensation Committee and Strategic Planning and Capital Allocation Committee. There are no arrangements or understandings between Ms. Kemps-Polanco and any other person pursuant to which she was selected as director, and there are no transactions in which Ms. Kemps-Polanco has an interest requiring disclosure under Item 404(a) of Regulation S-K. Ms. Kemps-Polanco will participate in the non-employee director compensation program arrangements generally applicable to all of the Company's non-employee directors.

   Read the 8-K filing
9. Jan 16, 2024

   On January 9, 2023, Charles River Laboratories International, Inc. (the “Company”) announced that William D. Barbo, its Corporate Executive Vice President and Chief Commercial Officer, will retire from the Company at the end of 2024 after a distinguished, 42-year career with the Company. In the interim, Mr. Barbo will continue to serve as an Executive Vice President and strategic advisor to the Company to ensure a smooth transition of his responsibilities. In connection with Mr. Barbo’s planned retirement, Kristen Eisenhauer is assuming the role of Senior Vice President, Chief Commercial Officer. Ms. Eisenhauer has been with the Company for 20 years and has held various leadership roles across the organization, from operations management, client services, sales, and marketing, including, most recently, as Corporate Senior Vice President, Safety Assessment Customer Excellence. 2

   Read the 8-K filing
10. Dec 6, 2022

    Effective December 5, 2022, the Board of Directors (the "Board") of Charles River Laboratories International, Inc., (the "Registrant") increased the size of the Board from ten to eleven. Following the size increase of the Board, the Board filled the vacancy and appointed Dr. Craig B. Thompson to the Board. Dr. Thompson has been appointed to the Registrant's existing Science and Technology Committee and Strategic Planning and Capital Allocation Committee. There are no arrangements or understandings between Dr. Thompson and any other person pursuant to which he was selected as director, and there are no transactions in which Dr. Thompson has an interest requiring disclosure under Item 404(a) of Regulation S-K. Dr. Thompson will participate in the non-employee director compensation program arrangements generally applicable to all of the Registrant's non-employee directors.

    Read the 8-K filing
11. Mar 28, 2022

    (b) As previously announced on January 11, 2022, David R. Smith intends to retire from Charles River Laboratories International, Inc. (the “Company”). Mr. Smith will step down from his position as Corporate Executive Vice President and Chief Financial Officer in connection with Flavia H. Pease’s appointment as the Company’s new Corporate Executive Vice President and Chief Financial Officer (as discussed below). Once Ms. Pease assumes the role of Chief Financial Officer, Mr. Smith will become Senior Financial Advisor and will remain with the Company until February 2023. (c), (e) On March 28, 2022, the Company announced the appointment of Flavia H. Pease as its Corporate Vice President and Chief Financial Officer. Ms.

    Read the 8-K filing
12. Jan 11, 2022

    On January 11, 2022, Charles River Laboratories International, Inc. (the “Company”) announced that David R. Smith, its Corporate Executive Vice President and Chief Financial Officer, will retire from the Company after a distinguished career in healthcare and finance leadership roles. Mr. Smith will remain with the Company in his current position until a successor has been named and the transition has been completed, which is expected to occur before the end of 2022. Mr. Smith joined Charles River in 2014 through the Discovery Services acquisition of Argenta and BioFocus. Following the acquisition, he assumed the role of Corporate Vice President, Early Discovery Services, and was subsequently named Corporate Senior Vice President, Global Discovery Services. In 2015, leveraging Mr. Smith’s extensive business, finance, and leadership experience, the Company promoted Mr.

    Read the 8-K filing
13. Dec 27, 2021

    On December 22, 2021, the Compensation Committee of the Board of Directors of Charles River Laboratories International, Inc. (the “Company”) approved a one-time, long-term equity award to Joseph W. LaPlume, Corporate Executive Vice President, Corporate Development & Strategy. The one-time award is intended to recognize Mr. LaPlume’s prior contributions to, and his continued critical role in, the growth of the Company, and to further incentivize him in connection with the achievement of the Company’s strategic business goals over the next five years. The effective grant date of the award is December 25, 2021. The award has an intended grant date fair value of $5,000,000, 50% of which will be issued in restricted stock units, substantially in the form of award typically awarded to executive officers, except that the award will vest on a cliff basis five years from the date of grant.

    Read the 8-K filing
14. Nov 12, 2021

    (c) On November 11, 2021, Charles River Laboratories International, Inc. (the "Company") announced that Ms. Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment and Biologics Testing Solutions, will become Chief Operating Officer of the Company, effective immediately, and will add Research Models and Services to her responsibilities. Ms. Girshick will continue to report directly to James C. Foster, Chairman, President and Chief Executive Officer. Ms. Girshick, age 51, has a proven track record of outstanding performance, leading many of the Company’s businesses through important strategic initiatives during her three decades with the Company. Ms. Girshick joined Charles River in 1989 and held positions of increasing responsibility in the Company’s Research Models and Services (RMS) Germany and Avian Vaccine Services businesses. In 2010, Ms.

    Read the 8-K filing
15. May 18, 2021

    (e) On May 18, 2021, Charles River Laboratories International, Inc. (the “Company”) announced that it had entered into an amended and restated employment agreement (the “employment agreement”), effective as of May 18, 2021 (the “Effective Date”), with James C. Foster. The purpose of the agreement is to continue to benefit from Mr. Foster’s decades of experience and unique skill set by promoting the retention of Mr. Foster. To this end, the employment agreement provides for Mr. Foster’s employment as the Chairman and Chief Executive Officer of the Company through February 12, 2026 (the “Employment Term”), which is three years longer than the original employment agreement. There are no other material changes provided by the amended and restated employment agreement that were not previously provided by the original employment agreement.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.